GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » Total Payout Ratio

ECOR (electroCore) Total Payout Ratio : 0.70 (As of Jul. 20, 2025)


View and export this data going back to 2018. Start your Free Trial

What is electroCore Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

electroCore's current Total Payout Ratio is 0.70.


electroCore Total Payout Ratio Historical Data

The historical data trend for electroCore's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

electroCore Total Payout Ratio Chart

electroCore Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only 0.74 1.49 - 0.43 0.70

electroCore Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.13 - - 0.06

Competitive Comparison of electroCore's Total Payout Ratio

For the Medical Devices subindustry, electroCore's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


electroCore's Total Payout Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, electroCore's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where electroCore's Total Payout Ratio falls into.


;
;

electroCore Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

electroCore's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 8.3 + 0) / -11.886
=0.70

electroCore's Total Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.217 + 0) / -3.855
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


electroCore Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of electroCore's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


electroCore Business Description

Traded in Other Exchanges
Address
200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Executives
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Thomas J. Errico director, 10 percent owner 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
Daniel S Goldberger director, officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Joseph P Errico director, 10 percent owner, officer: See Remarks 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Trevor J Moody director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Julie Ann Goldstein director 205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber director 205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner officer: Chief Financial Officer 1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L director 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo director 10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033